Competitive and non-competitive effects of 5-hydroxyindole on 5-HT3 receptors in N1E-115 neuroblastoma cells. 1994

A R Kooyman, and J A van Hooft, and P M Vanderheijden, and H P Vijverberg
Research Institute of Toxicology, Utrecht University, The Netherlands.

1. Effects of 5-hydroxyindole (5-OH-indole) (the aromatic moiety of 5-hydroxytryptamine (5-HT)) on 5-HT-evoked ion current and the nature of these effects on 5-HT3 receptors have been investigated in whole-cell voltage clamp and radioligand binding experiments on cultured N1E-115 mouse neuroblastoma cells. 2. The amplitude of 10 microM 5-HT-evoked ion currents was enhanced up to 150% of the control value by increasing concentrations up to 10 mM 5-OH-indole with half maximum effect of 0.8 mM. At concentrations between 10 mM and 50 mM, 5-OH-indole blocked the 5-HT-evoked ion current. Both the enhancement and the block by 5-OH-indole were accompanied by a marked slowing of the kinetics of decay of the 5-HT-evoked inward currents. 3. The blocking effect was surmounted when the 5-HT concentration was raised from 10 microM to 100 microM. Conversely, the increase in amplitude and the slowing of the decay of the 5-HT-evoked ion current induced by 1 mM 5-OH-indole were not reversed by the same increase of 5-HT concentration. 4. The binding of the selective antagonist [3H]-GR65630 to 5-HT3 receptors was displaced by 5-OH-indole in a concentration-dependent manner with a pKi of 1.96. In saturation binding experiments 10 mM 5-OH-indole reduced the affinity of [3H]-GR65630, whereas the total number of binding sites remained unaffected. 5. It is concluded that the blocking effect of high concentrations of 5-OH-indole is due to a competitive interaction with the antagonist recognition sites of 5-HT3 receptors, whereas the potentiating effect of lower concentrations of 5-OH-indole appears to be mediated by a distinct non-competitive interaction.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D011985 Receptors, Serotonin Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action. 5-HT Receptor,5-HT Receptors,5-Hydroxytryptamine Receptor,5-Hydroxytryptamine Receptors,Receptors, Tryptamine,Serotonin Receptor,Serotonin Receptors,Tryptamine Receptor,Tryptamine Receptors,Receptors, 5-HT,Receptors, 5-Hydroxytryptamine,5 HT Receptor,5 HT Receptors,5 Hydroxytryptamine Receptor,5 Hydroxytryptamine Receptors,Receptor, 5-HT,Receptor, 5-Hydroxytryptamine,Receptor, Serotonin,Receptor, Tryptamine,Receptors, 5 HT,Receptors, 5 Hydroxytryptamine
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D004594 Electrophysiology The study of the generation and behavior of electrical charges in living organisms particularly the nervous system and the effects of electricity on living organisms.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding

Related Publications

A R Kooyman, and J A van Hooft, and P M Vanderheijden, and H P Vijverberg
September 1990, European journal of pharmacology,
A R Kooyman, and J A van Hooft, and P M Vanderheijden, and H P Vijverberg
January 1994, Neuropharmacology,
A R Kooyman, and J A van Hooft, and P M Vanderheijden, and H P Vijverberg
April 1996, British journal of pharmacology,
A R Kooyman, and J A van Hooft, and P M Vanderheijden, and H P Vijverberg
September 1990, European journal of pharmacology,
A R Kooyman, and J A van Hooft, and P M Vanderheijden, and H P Vijverberg
January 1997, Neuropharmacology,
A R Kooyman, and J A van Hooft, and P M Vanderheijden, and H P Vijverberg
October 1993, European journal of pharmacology,
A R Kooyman, and J A van Hooft, and P M Vanderheijden, and H P Vijverberg
January 1997, Neuropharmacology,
A R Kooyman, and J A van Hooft, and P M Vanderheijden, and H P Vijverberg
October 1991, British journal of pharmacology,
A R Kooyman, and J A van Hooft, and P M Vanderheijden, and H P Vijverberg
July 1988, European journal of pharmacology,
A R Kooyman, and J A van Hooft, and P M Vanderheijden, and H P Vijverberg
May 1986, Acta physiologica Scandinavica,
Copied contents to your clipboard!